Daily Ards Research Analysis
Analyzed 10 papers and selected 3 impactful papers.
Summary
Three impactful ARDS studies span preclinical therapeutics and clinical management. A biomimetic, inhaled nanoplatform reprograms alveolar macrophage metabolism via the BMAL1/PFKFB3 axis to rescue SA-ARDS in mice; a multicenter cohort shows antifungals reduce 60-day mortality in CAPA; and PPARβ/δ-licensed MSC secretomes enhance ANGPTL4-mediated lung protection in ALI models.
Research Themes
- Targeted metabolic reprogramming of alveolar macrophages in SA-ARDS
- Effectiveness of antifungal therapy in COVID-19-associated pulmonary aspergillosis
- Engineering MSC secretomes via PPARβ/δ-ANGPTL4 for ARDS therapy
Selected Articles
1. Tetrahedral DNA Nanostructure-Based Biomimetic Nanovesicles Attenuate Sepsis-Associated ARDS by Suppressing Glycolysis via the BMAL1/PFKFB3 Axis.
This preclinical study establishes BMAL1 as a macrophage-centric therapeutic node in SA-ARDS and demonstrates an inhalable, AM-targeted nanovesicle that activates BMAL1 to repress PFKFB3-driven glycolysis. The treatment reduced lung inflammation, edema, and improved survival in murine SA-ARDS, highlighting a translatable metabolic-immunologic strategy.
Impact: It uncovers a circadian-metabolic checkpoint (BMAL1/PFKFB3) in ARDS pathobiology and delivers a targeted, inhalable nanotherapy with survival benefit in vivo.
Clinical Implications: While preclinical, the work supports inhaled, macrophage-targeted metabolic reprogramming in SA-ARDS and prioritizes BMAL1 activation as a therapeutic avenue warranting translational development and safety testing.
Key Findings
- BMAL1 represses PFKFB3, limiting glycolysis and M1 polarization in alveolar macrophages.
- An inhalable biomimetic nanoplatform (RM@TNT) targets AMs and activates BMAL1 in a ROS-rich lung microenvironment.
- RM@TNT reduced lung inflammation, injury, and edema and significantly improved survival in SA-ARDS mice.
Methodological Strengths
- Mechanistic validation of BMAL1→PFKFB3 axis with targeted delivery to AMs.
- In vivo efficacy with survival benefit using disease-relevant inhalation route.
Limitations
- Preclinical murine model; species differences may limit translatability.
- Safety, biodistribution, and manufacturability of the nanoplatform were not fully characterized.
Future Directions: Conduct GLP toxicology, pharmacokinetics, and dose-ranging studies, refine inhalation formulations, and explore biomarkers (BMAL1/PFKFB3 activity) to enable early-phase clinical trials in SA-ARDS.
Sepsis-associated acute respiratory distress syndrome (SA-ARDS) is a life-threatening complication characterized by excessive pulmonary inflammation and pulmonary edema, lacking effective treatments. This study identifies the transcription factor BMAL1 in alveolar macrophages (AMs) as a key therapeutic target. Mechanistically, BMAL1 represses the expression of the glycolytic enzyme PFKFB3 by binding to the Pfkfb3 promoter, thereby inhibiting glycolysis, M1 polarization of AMs, and the generation of pro-inflammatory cytokines and reactive oxygen species (ROS). Based on this regulatory mechanism, a biomimetic nanoplatform, RM@TNT, is engineered for precise SA-ARDS therapy. Fabricated by hybridizing AM membrane-derived nanovesicles with ROS-responsive liposomes, the nanoplatform encapsulates tetrahedral DNA nanostructures (TNT) preloaded with nobiletin (Nob, a BMAL1 agonist) and Tuftsin (an AM-targeting peptide). Following inhalation, the AM membrane tropism of RM@TNT ensures prolonged pulmonary retention, prompting targeted TNT release within the ROS-rich pathological microenvironment. Tuftsin then precisely delivers TNT to AMs, where Nob is intracellularly released to activate BMAL1. This activation upregulates the BMAL1/PFKFB3 axis, suppressing AM glycolysis, inflammation, and oxidative stress. Treatment with RM@TNT resulted in significantly attenuated lung inflammation, injury, and edema, along with markedly improved survival in SA-ARDS mice. Collectively, this multimodal, targeted metabolic reprogramming approach is a highly promising therapeutic strategy for SA-ARDS.
2. Effects of antifungal treatment in COVID-19-associated pulmonary aspergillosis: A European multicenter cohort study.
In 259 ICU patients with probable/proven CAPA across European centers, antifungal therapy—predominantly azoles—was associated with substantially lower 60-day mortality after propensity weighting (HR 0.28). Age, immunosuppression, and remdesivir were associated with higher mortality, while male sex and antifungal therapy were protective.
Impact: Provides multicenter, methodologically robust evidence supporting antifungal therapy in CAPA, a frequent complication in severe COVID-19/ARDS care.
Clinical Implications: Clinicians should maintain high suspicion for CAPA in ventilated COVID-19/ARDS patients and initiate timely antifungal therapy alongside rapid diagnostics, especially in immunosuppressed individuals.
Key Findings
- Among 259 CAPA cases, antifungal treatment was associated with lower 60-day mortality (weighted HR 0.28, 95% CI 0.13–0.58, p<0.001).
- Age, immunosuppressive therapy, and remdesivir were independently associated with increased 60-day mortality.
- Male sex and receipt of antifungal therapy were associated with lower 60-day mortality in Cox models.
Methodological Strengths
- Multicenter cohort with propensity score-based inverse probability weighting.
- Consistent findings across raw and weighted Cox regression analyses.
Limitations
- Observational design with potential residual confounding and treatment selection bias.
- Heterogeneity in CAPA diagnostics and antifungal regimens across centers; timing of therapy initiation may vary.
Future Directions: Prospective randomized trials and standardized diagnostic/treatment pathways for CAPA; evaluate optimal antifungal choice, timing, and duration, and stratify by immunosuppression.
BACKGROUND: The management of COVID-19-associated invasive aspergillosis (CAPA) is still debated while cases continue to occur, and more and more frequently in vulnerable populations, stressing the importance of obtaining data on the treatment of this disease. Only small cohort studies and case-reports have yet discussed this essential issue and data obtained are insufficient to conclude with confidence. RESEARCH QUESTION: Is antifungal treatment associated with lower 60-day mortality in patients with probable or proven CAPA? STUDY DESIGN AND METHODS: We assessed the association of antifungal treatment with 60-day mortality for probable/proven CAPA cases from a French multicenter study and all consecutive CAPA cases (post-2020) from intensive care units of five major European centers. Patients were compared according to antifungal treatment. Survival analysis was conducted using Cox regression analysis and inverse probability of treatment weighting based on a propensity score. RESULTS: In total, 259 CAPA patients were included, 237 (91.5%) receiving antifungals for CAPA of whom 215 (90.7%) received azole antifungal drugs. Baseline characteristics were similar between patients who received antifungals and those who did not. Age (HR 1.02, 95%CI:1.00-1.04, p=0.048), immunosuppressive treatment (HR 2.08, 95%CI:1.12-3.41, p<0.001], and remdesivir administration (HR 1.96, 95%CI:1.12-3.41, p=0.018) were independently associated with increased 60-day mortality by Cox regression analysis in the raw population. Male sex (HR 0.61, 95%CI:0.40-0.95, p=0.024) and antifungal treatment (HR 0.31, 95%CI:0.17-0.59, p<0.001) were associated with lower 60-day mortality. Cox-weighted regression showed lower 60-day mortality for patients receiving antifungals (weighted HR 0.28 [95%CI:0.13-0.58], p<0.001. INTERPRETATION: We observed that antifungal treatment was associated with lower 60-day mortality in CAPA patients. The high mortality rate observed in CAPA in immunocompromised patients and improved outcome for treated patients should encourage clinicians to actively screen for CAPA to enable rapid diagnosis and targeted treatment.
3. The PPARβ/Delta-Induced Mesenchymal Stromal Cell Secretome Has Cytoprotective Effects via ANGPTL4 in a Pre-Clinical Model of Acute Lung Inflammation.
PPARβ/δ agonism and ARDS-serum licensing of hBM-MSCs amplified ANGPTL4 within the MSC secretome, enhancing epithelial repair and endothelial barrier integrity in vitro and in LPS-induced ALI mice. Neutralization of ANGPTL4 abrogated protection, establishing ANGPTL4 as a key effector of MSC-based cytoprotection.
Impact: Demonstrates a tunable MSC secretome mechanism via ANGPTL4 and provides a practical licensing strategy to potentiate cell-free therapeutics for ARDS.
Clinical Implications: Supports development of PPARβ/δ-primed, ARDS-licensed MSC secretome products as cell-free therapeutics to restore lung barrier function; ANGPTL4 is a mechanistic potency marker and potential co-therapeutic target.
Key Findings
- PPARβ/δ agonized hBM-MSC secretome increased ANGPTL4 and enhanced epithelial repair in CALU-3 cells.
- ANGPTL4-high MSC secretome improved pulmonary endothelial barrier integrity in LPS-induced ALI mice.
- Licensing MSCs with ARDS patient serum further augmented therapeutic effects; anti-ANGPTL4 antibody abrogated protection.
Methodological Strengths
- Integrated in vitro epithelial and in vivo ALI models with mechanistic validation via ANGPTL4 neutralization.
- Clinically relevant licensing using human ARDS serum to enhance MSC secretome potency.
Limitations
- LPS-induced ALI may not fully recapitulate human ARDS heterogeneity.
- Translational aspects such as dosing, manufacturing consistency, and safety profiling of secretome products remain to be defined.
Future Directions: Standardize secretome production and potency assays, test across diverse ARDS models, and evaluate ANGPTL4 as a release criterion and as a co-therapeutic in early translational studies.
Human bone marrow-derived mesenchymal stromal cells (hBM-MSCs) are known to exert immunomodulatory and pro-reparative effects in vivo. This makes hBM-MSCs an enticing therapeutic candidate for inflammatory diseases, such as acute respiratory distress syndrome (ARDS). The ARDS microenvironment is complex and contains an abundance of free fatty acids (FFAs), which are known to differentially impact MSC functionality. PPARβ/δ is a ubiquitously expressed nuclear receptor that is activated in response to FFA-binding. PPARβ/δ has been shown to impact the therapeutic efficacy of mouse MSCs. This study sought to investigate the impact of PPARβ/δ-modulation on human MSC functionality in vitro and in vivo. hBM-MSCs were exposed to a synthetic PPARβ/δ agonist/antagonist in the presence or absence of ARDS patient serum and the immunomodulatory and pro-reparative capacity of the MSC secretome was investigated using in vitro assays and a pre-clinical model of LPS-induced acute lung inflammation (ALI). Our results highlighted enhanced pro-reparative capacity of PPARβ/δ-agonized hBM-MSCs secretome in CALU-3 lung epithelial cells, mediated by MSC derived angiopoietin-like 4 (ANGPTL4). PPARβ/δ-induced ANGPTL4-high MSC secretome facilitated enhanced endothelial barrier integrity in the lungs of ALI mice. Therapeutic effects of PPARβ/δ-agonized hBM-MSCs secretome were further enhanced by licensing MSCs with human ARDS patient serum. ARDS-licensed PPARβ/δ-induced ANGPTL4-high MSC secretome had reduced clinical score and weight loss. The role ANGPL4 in these protective effects was confirmed using an anti-ANGPTL4 antibody. These findings conclude that the MSC secretome therapeutic effects can be enhanced both in vitro and in vivo through licensing strategies that upregulate the angiogenic factor ANGPTL4.